Compare · NVO vs SYRE
NVO vs SYRE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $197.31B, about 25.7x SYRE ($7.66B).
- SYRE has been more active in the news (9 items in the past 4 weeks vs 6 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for SYRE).
- Company
- Novo Nordisk A/S
- Spyre Therapeutics Inc.
- Price
- -
- -
- Market cap
- $197.31B
- $7.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SYRE
- Spyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
- Spyre Therapeutics Announces Grants of Inducement Awards
- Officer King-Jones Heidy exercised 28,399 shares at a strike of $14.50 and sold $2,480,529 worth of shares (28,399 units at $87.35) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $2,283,821 worth of shares (25,732 units at $88.75) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,762 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Turtle Cameron sold $1,309,410 worth of shares (15,000 units at $87.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 552,540 units (SEC Form 4)
- Spyre Therapeutics to Participate in Upcoming September Investor Conferences
- Spyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
- Amendment: SEC Form SCHEDULE 13G/A filed by Spyre Therapeutics Inc.